HTC 340B Utilization and Reimbursement
1.
The purpose of this survey is to provide information on both the direct and indirect ways in which the 340B drug discount program benefits your organization, its patients and your community. Please submit responses by Friday, April 29. If you have questions at any point, please contact Sean Singh at sean@hemoalliance.org or 727-388-7326 and we will be happy to help you.
If your organization has ever conducted any internal valuations of the value of 340B, such as a report to the CFO or your Board, and if your organization is able to share the evaluation with us, we would be very interested in receiving a copy. Please email the document to Joe Pugliese at joe@hemoalliance.org.
Please note that to ensure that the survey reaches the appropriate contact, this survey may have been sent to more than one person at your institution if we had multiple contacts in our database. You should confer with your colleagues before completing the survey to ensure that
each institution submits only one response. Please also note that you have the option of responding as individual hospitals or as a system if appropriate. To avoid duplicates if submitting as a system, please make sure the individual hospitals in your system do not answer the survey as well.
| | (1) Not Important | (2) | (3) Important | (4) | (5) Critically Important |
|---|
| Rating | | | | | |
|---|